Onderneming BioCardia Inc Nasdaq
Aandelen
US09060U1016
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100,0
%
| 1 | 100,0 % | 0 | 100,0 % | -64,72% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 1 | 100,0 % | 0 | 100,0 % | -64,72% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Peter Altman
CEO | Chief Executive Officer | 57 | 01-01-02 |
David McClung
DFI | Director of Finance/CFO | 61 | 01-09-13 |
Chief Tech/Sci/R&D Officer | - | 01-08-17 | |
Sujith Shetty
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-19 |
Ian McNiece
CTO | Chief Tech/Sci/R&D Officer | 70 | 08-11-17 |
Anne Laluc
IRO | Public Communications Contact | - | - |
Mark Schwartz
PRN | Corporate Officer/Principal | - | 01-11-18 |
Edward Gillis
PRN | Corporate Officer/Principal | 62 | 01-01-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Simon Stertzer
BRD | Director/Board Member | 88 | 01-01-02 |
Jay Moyes
BRD | Director/Board Member | 70 | 01-01-11 |
Richard Krasno
BRD | Director/Board Member | 82 | 24-10-16 |
Director/Board Member | 53 | 18-10-23 | |
Peter Altman
CEO | Chief Executive Officer | 57 | 01-01-02 |
Andrew Blank
CHM | Chairman | 68 | 01-10-19 |
Jim Allen
BRD | Director/Board Member | 69 | 01-10-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 27 304 116 | 19 255 345 ( 70,52 %) | 0 | 70,52 % |
Bedrijfsgegevens
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,58% | 115 mld. | |
+12,41% | 106 mld. | |
-2,59% | 21,96 mld. | |
-12,38% | 21,87 mld. | |
-5,29% | 19,21 mld. | |
-3,35% | 18,08 mld. | |
-38,57% | 17,71 mld. | |
+7,51% | 14,32 mld. | |
+35,67% | 12,42 mld. |
- Beurs
- Aandelen
- Koers BCDA
- Koers
- Onderneming BioCardia Inc